On January 4, 2018, Abattis Bioceuticals Corp. (OTCPK:ATTB.F) closed the transaction. The company issued 6,310,048 units at a price of CAD 0.43 per unit for gross proceeds of CAD 2,713,321 in the second tranche of the transaction. The company utilized its over-allotment provision. The company issued 15,612,371 units at a price of CAD 0.43 per unit and received a total of CAD 6,713,320 in the transaction.